Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Equillium Inc expects to begin dosing patients in its first-in-human clinical trial of Eq504 in Australia by early November 2026, with topline Phase 1 data expected six months after study initiation.
Equillium has received Australian regulatory clearance to initiate a first-in-human clinical trial for its EQ504 drug. The randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of EQ504 in healthy subjects. Dosing is expected to begin by early